Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 2495
Biosimilarity between Humira® and the Biosimilar Candidate SB5 in Product Quality
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2110
Blood Group ”a“ Was Increased in FMF Patients and Blood Group ”0“ May be Associated with Colchicine Resistance
Miscellaneous Rheumatic and Inflammatory Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 2378
Body Mass Index and Persistence of Conventional Dmards and TNF Inhibitors in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2671
Bosentan in Scleroderma Renal Crisis: A National Open Label Prospective Study
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III- 9:00AM-11:00AM
-
Abstract Number: 2319
Bradycardia after High-Dose Solu-Medrol
ARHP Pediatric Rheumatology – Clinical Aspects Poster- 9:00AM-11:00AM
-
Abstract Number: 2561
BTK Inhibition Ameliorates Renal Disease in Spontaneous Murine Lupus Nephritis
Systemic Lupus Erythematosus – Animal Models Poster- 9:00AM-11:00AM
-
Abstract Number: 1958
Burden of Rheumatic Disease Among Korean Women in Childbearing Years Based on the National Health Insurance Service-National Sample Cohort
Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes- 9:00AM-11:00AM
-
Abstract Number: 2117
C-Reactive Protein and Serum Amyloid a in Sepsis, Acute Appendicitis and Familial Mediterranean Fever
Miscellaneous Rheumatic and Inflammatory Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 2086
Calcium Pyrophosphate Crystal Size, Shape and Appearance Variability
Metabolic and Crystal Arthropathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 2244
Can Achieving Remission Improve Work Ability and Quality of Life in Early Rheumatoid Arthritis (RA) Patients? a Prospective Cohort Study
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2545
Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Two-Year Prospective Cohort Study in Psoriatic Arthritis
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2719
Can Annexin A1 Expression on Neutrophils Distinguish Adult IgA Vasculitis from Other Small Vessel Vasculitides?
Vasculitis Poster III: Other Vasculitis Syndromes- 9:00AM-11:00AM
-
Abstract Number: 2293
Can We Predict Achievement of Clinically Inactive Disease and Sustained Remission in Children with Juvenile Idiopathic Arthritis?
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 2182
Cardiovascular Events in Patients with Diffuse Idiopathic Skeletal Hyperostosis. a 10 Years Follow-up Study